136 related articles for article (PubMed ID: 38018179)
1. Development of 7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives Using QSARINS Tool as BTK Inhibitors for the Treatment of Rheumatoid Arthritis.
Patil SM; Asgaonkar KD; Magdum P; Chinde V; Edake A; Naik A
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(4):236-249. PubMed ID: 38018179
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
4. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Xu A; Zhang Y; Ran T; Liu H; Lu S; Xu J; Xiong X; Jiang Y; Lu T; Chen Y
SAR QSAR Environ Res; 2015; 26(4):279-300. PubMed ID: 25906044
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening and structure-activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis.
Sun L; Wang Z; Yang Z; Liu X; Dong H
J Biomol Struct Dyn; 2023; 41(24):15219-15233. PubMed ID: 36914235
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors.
Joshi D; Bahekar R; Soman S; Jadav P; Patel D; Goswami A; Pethani J; Kumar J; Patel J; Sundar R; Goswami P; Goshdastidar K; Patel H; Patel A; Bandyopadhyay D; Chattarjee A; Sharma M; Jain M; Desai R
Bioorg Chem; 2023 Jan; 130():106238. PubMed ID: 36403335
[TBL] [Abstract][Full Text] [Related]
8. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
Zhao G; Liu A; Zhang Y; Zuo ZQ; Cao ZT; Zhang HB; Xu CF; Wang J
Biomater Sci; 2019 Nov; 7(11):4698-4707. PubMed ID: 31495833
[TBL] [Abstract][Full Text] [Related]
10. 4D-QSAR Models Applied to the Study of TGF- β1 Receptor Inhibitors.
Maria de Assis T; Ramalho TC; Ferreira da Cunha EF
Curr Top Med Chem; 2021; 21(13):1157-1166. PubMed ID: 34315368
[TBL] [Abstract][Full Text] [Related]
11. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
Evans EK; Tester R; Aslanian S; Karp R; Sheets M; Labenski MT; Witowski SR; Lounsbury H; Chaturvedi P; Mazdiyasni H; Zhu Z; Nacht M; Freed MI; Petter RC; Dubrovskiy A; Singh J; Westlin WF
J Pharmacol Exp Ther; 2013 Aug; 346(2):219-28. PubMed ID: 23709115
[TBL] [Abstract][Full Text] [Related]
17. Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.
Li R; Du Y; Gao Z; Shen J
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671827
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.
Keretsu S; Bhujbal SP; Cho SJ
J Biomol Struct Dyn; 2021 Feb; 39(3):753-765. PubMed ID: 31916502
[TBL] [Abstract][Full Text] [Related]
19. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Pery N; Rizvi NB; Shafiq MI
J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
[TBL] [Abstract][Full Text] [Related]
20. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
Ma W; Wang Y; Chu D; Yan H
J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
